Histamine: An undercover agent in multiple rare diseases?

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 1947-1960

  Pino Ángeles, Almudena ^a,b   Reyes Palomares, Armando ^a   Melgarejo, Esther ^a,b   Sánchez Jiménez, Francisca ^a,b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Histamine; Histamine receptors; Rare diseases; Systems biology

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE RECEPTOR; HISTIDINE DECARBOXYLASE;

ARTICLE; DATA MINING; DRUG EFFECT; HUMAN; INFLAMMATION; METABOLISM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; RARE DISEASE; SIGNAL TRANSDUCTION; STOMACH JUICE; SYNAPTIC TRANSMISSION; SYSTEMS BIOLOGY;

DATA MINING; GASTRIC JUICE; HISTAMINE; HISTIDINE DECARBOXYLASE; HUMANS; INFLAMMATION; NERVOUS SYSTEM DISEASES; RARE DISEASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYSTEMS BIOLOGY;

EID: 84865418774     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01566.x     Document Type: Article

References (143)

1. Shahid M, Tripathi T, Khan R, et al. Biological and pharmacological aspects of histamine receptors and their ligands. In: Shahid M KN, Khan RA, Tripathi T, editors. Biomedical aspects of histamine: current perspectives. London: Springer; 2010: p. 61-91.
2. Moya-Garcia AA, Medina MA, Sanchez-Jimenez F. Mammalian histidine decarboxylase: from structure to function. Bioessays. 2005; 27: 57-63.
3. Moya-Garcia AA, Ruiz-Pernia J, Marti S, et al. Analysis of the decarboxylation step in mammalian histidine decarboxylase. A computational study. J Biol Chem. 2008; 283: 12393-401.
4. Garcia-Faroldi G, Rodriguez CE, Urdiales JL, et al. Polyamines are present in mast cell secretory granules and are important for granule homeostasis. PLoS One. 2010; 5: e15071.
5. Abrighach H, Fajardo I, Sanchez-Jimenez F, et al. Exploring polyamine regulation by nascent histamine in a human-transfected cell model. Amino Acids. 2010; 38: 561-73.
6. Ochiai Y, Itoh K, Sakurai E, et al. Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems. Biol Pharm Bull. 2006; 29: 2362-6.
7. Ogasawara M, Yamauchi K, Satoh Y, et al. Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci. 2006; 101: 24-30.
8. Schneider E, Bertron AF, Dy M. Modulation of hematopoiesis through histamine receptor signaling. Front Biosci (Schol Ed). 2011; 3: 467-73.
9. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008; 7: 41-53.
10. Leurs R, Chazot PL, Shenton FC, et al. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol. 2009; 157: 14-23.
11. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006; 533: 69-76.
12. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008; 88: 1183-241.
13. Arrang JM, Morisset S, Gbahou F. Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci. 2007; 28: 350-7.
14. Connelly WM, Shenton FC, Lethbridge N, et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol. 2009; 157: 55-63.
15. Musio S, Gallo B, Scabeni S, et al. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J Immunol. 2006; 176: 17-26.
16. Mondillo C, Falus A, Pignataro O, et al. Prolonged histamine deficiency in histidine decarboxylase gene knockout mice affects Leydig cell function. J Androl. 2007; 28: 86-91.
17. Burgess CR. Histamine and orexin in the control of arousal, locomotion, and motivation. J Neurosci. 2010; 30: 2810-1.
18. Sakurai E, Kuramasu A, Watanabe T, et al. Multiple histamine receptor gene knockout mice and their phenotypes. Inflamm Res. 2009; 58(Suppl 1): 41-2.
19. Moya-Garcia AA, Pino-Angeles A, Gil-Redondo R, et al. Structural features of mammalian histidine decarboxylase reveal the basis for specific inhibition. Br J Pharmacol. 2009; 157: 4-13.
20. Wijtmans M, de Graaf C, de Kloe G, et al. Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity. J Med Chem. 2011; 54: 1693-703.
21. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol. 2007; 25: 1119-26.
22. Tanabe M, Sakura N. Hyperhistaminemia in patients with histidinemia due to increased decarboxylation of histidine. Clin Chim Acta. 1989; 186: 11-7.
23. Krauth MT, Agis H, Aichberger KJ, et al. Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. Hum Pathol. 2006; 37: 439-47.
24. Wardlaw R, Smith JW. Gastric carcinoid tumors. Ochsner J. 2008; 8: 191-6.
25. Raithel M, Nagel A, Zopf Y, et al. Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD). Inflamm Res. 2010; 59: S257-8.
26. Roubertoux PL, de Vries PJ. From molecules to behavior: lessons from the study of rare genetic disorders. Behav Genet. 2011; 41: 341-8.
27. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA. 2007; 104: 8685-90.
28. Zhang M, Zhu C, Jacomy A, et al. The orphan disease networks. Am J Hum Genet. 2011; 88: 755-66.
29. Medina MA, Correa-Fiz F, Rodriguez-Caso C, et al. A comprehensive view of polyamine and histamine metabolism to the light of new technologies. J Cell Mol Med. 2005; 9: 854-64.
30. Ananiadou S, Kell DB, Tsujii J. Text mining and its potential applications in systems biology. Trends Biotechnol. 2006; 24: 571-9.
31. Sanchez-Jimenez F, Montanez R, Correa-Fiz F, et al. The usefulness of post-genomics tools for characterization of the amine cross-talk in mammalian cells. Biochem Soc Trans. 2007; 35: 381-5.
32. Hur J, Schuyler AD, States DJ, et al. SciMiner: web-based literature mining tool for target identification and functional enrichment analysis. Bioinformatics. 2009; 25: 838-40.
33. Bachrach CA, Charen T. Selection of MEDLINE contents, the development of its thesaurus, and the indexing process. Med Inform. 1978; 3: 237-54.
34. Neveol A, Shooshan SE, Claveau V. Automatic inference of indexing rules for MEDLINE. BMC Bioinformatics. 2008; 9(Suppl 11): S11.
35. Neveol A, Shooshan SE, Humphrey SM, et al. A recent advance in the automatic indexing of the biomedical literature. J Biomed Inform. 2009; 42: 814-23.
36. O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol. 2011; 128: 1153-62.
37. Chazot PL. Advances in histamine pharmacology reveal new drug targets. Br J Pharmacol. 2009; 157: 1-3.
38. Suwa E, Yamaura K, Oda M, et al. Histamine H(4) receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur J Pharmacol. 2011; 667: 383-8.
39. Nakamura Y, Kambe N, Saito M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med. 2009; 206: 1037-46.
40. Lasiglie D, Traggiai E, Federici S, et al. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One. 2011; 6: e20014.
41. Simon T, Laszlo V, Lang O, et al. Histamine regulates relevant murine dendritic cell functions via H4 receptor. Front Biosci. 2011; 3: 1414-24.
42. de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 2005; 52: 687-93.
43. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-76.
44. Conti P, Kempuraj D, Di Gioacchino M, et al. Interleukin-6 and mast cells. Allergy Asthma Proc. 2002; 23: 331-5.
45. Ales K, Wraber B, Lipnik-Stangelj M. The synergistic effect of histamine and IL-6 on NGF secretion from cultured astrocytes is evoked by histamine stimulation of IL-6 secretion via H1-receptor-PKC-MAPK signalling pathway. Inflamm Res 2008; 57: S33-4.
46. Lindsley CB, Miner PB Jr. Seronegative juvenile rheumatoid arthritis and mast cell-associated gastritis. Arthritis Rheum. 1991; 34: 106-9.
47. Desai P, Thurmond RL. Histamine H(4) receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation. Eur J Immunol. 2011; 41: 1764-73.
48. Dunford PJ, O'Donnell N, Riley JP, et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol. 2006; 176: 7062-70.
49. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002; 168: 5984-8.
50. Xia T, Wang QR, Xu YH. Cimetidine inhibits production of interferon gamma and tumor necrosis factor alpha by splenocytes in aplastic anemic mice. Acta Pharmacol Sin. 2001; 22: 239-42.
51. Gantner F, Sakai K, Tusche MW, et al. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther. 2002; 303: 300-7.
52. Leite-de-Moraes MC, Diem S, Michel ML, et al. Cutting edge: histamine receptor H4 activation positively regulates in vivo IL-4 and IFN-gamma production by invariant NKT cells. J Immunol. 2009; 182: 1233-6.
53. Winterkamp S, Weidenhiller M, Otte P, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol. 2002; 97: 3071-7.
54. Fogel WA, Lewinski A, Jochem J. Histamine in idiopathic inflammatory bowel diseases - not a standby player. Folia Med Cracov. 2005; 46: 107-18.
55. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci. 2011; 32: 242-9.
56. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther. 2007; 113: 1-15.
57. Celanire S, Wijtmans M, Talaga P, et al. Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today. 2005; 10: 1613-27.
58. Moya-Garcia AA, Rodriguez CE, Morilla I, et al. The function of histamine receptor H4R in the brain revealed by interaction partners. Front Biosci. 2011; 3: 1058-66.
59. Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev. 2011; 15: 65-74.
60. Yasuko S, Atanda AM, Masato M, et al. Alpha-fluoromethylhistidine, a histamine synthesis inhibitor, inhibits orexin-induced wakefulness in rats. Behav Brain Res. 2010; 207: 151-4.
61. Sundvik M, Kudo H, Toivonen P, et al. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J. 2011; 25: 4338-47.
62. Anaclet C, Parmentier R, Ouk K, et al. Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci. 2009; 29: 14423-38.
63. Grimaldi D, Agati P, Pierangeli G, et al. Hypocretin deficiency in narcolepsy with cataplexy is associated with a normal body core temperature modulation. Chronobiol Int. 2010; 27: 1596-608.
64. Wallace TL, Ballard TM, Pouzet B, et al. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav. 2011; 99: 130-45.
65. Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-histidine decarboxylase and Tourette's syndrome. N Engl J Med. 2010; 362: 1901-8.
66. Ligneau X, Landais L, Perrin D, et al. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol. 2007; 73: 1215-24.
67. Yanovsky Y, Li S, Klyuch BP, et al. L-Dopa activates histaminergic neurons. J Physiol. 2011; 589: 1349-66.
68. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993; 33: 639-77.
69. Ito C, Onodera K, Sakurai E, et al. The effect of methamphetamine on histamine level and histidine decarboxylase activity in the rat brain. Brain Res. 1996; 734: 98-102.
70. Kubota Y, Ito C, Sakurai E, et al. Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. J Neurochem. 2002; 83: 837-45.
71. Morisset S, Pilon C, Tardivel-Lacombe J, et al. Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J Pharmacol Exp Ther. 2002; 300: 621-8.
72. Morisset S, Rouleau A, Ligneau X, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature. 2000; 408: 860-4.
73. Acevedo SF, Pfankuch T, van Meer P, et al. Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain. J Neurochem. 2008; 107: 976-86.
74. Chang L, Smith LM, LoPresti C, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res. 2004; 132: 95-106.
75. Lucotte G, Lagarde JP, Funalot B, et al. Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families. Clin Genet. 2006; 69: 437-40.
76. Klein C, Gurvich N, Sena-Esteves M, et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol. 2000; 47: 369-73.
77. Durr A, Tassin J, Vidailhet M, et al. D2 dopamine receptor gene in myoclonic dystonia and essential myoclonus. Ann Neurol. 2000; 48: 127-8.
78. Ferrada C, Ferre S, Casado V, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology. 2008; 55: 190-7.
79. Moreno E, Hoffmann H, Gonzalez-Sepulveda M, et al. Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem. 2011; 286: 5846-54.
80. Ledesma MC, Garcia-Martin E, Alonso-Navarro H, et al. The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med. 2008; 10: 356-61.
81. Keeling BH, Vilarino-Guell C, Soto-Ortolaza AI, et al. Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. Parkinsonism Relat Disord. 2010; 16: 112-4.
82. Marasovic-Susnjara I, Palada V, Marinovic-Terzic I, et al. No association between histamine N-methyltransferase functional polymorphism Thr105Ile and Alzheimer's disease. Neurosci Lett. 2011; 489: 119-21.
83. Lipnik-Stangelj M. Multiple role of histamine H1-receptor-PKC-MAPK signalling pathway in histamine-stimulated nerve growth factor synthesis and secretion. Biochem Pharmacol. 2006; 72: 1375-81.
84. Capsoni S, Covaceuszach S, Marinelli S, et al. Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS One. 2011; 6: e17321.
85. Carvalho OP, Thornton GK, Hertecant J, et al. A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. J Med Genet. 2011; 48: 131-5.
86. Stampachiacchiere B, Marinova T, Velikova K, et al. Altered levels of nerve growth factor in the thymus of subjects with myasthenia gravis. J Neuroimmunol. 2004; 146: 199-202.
87. Einarsdottir E, Carlsson A, Minde J, et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet. 2004; 13: 799-805.
88. Wang ZY, Ding Y, Miki T, et al. Nerve growth factor and receptors are significantly affected by histamine stimulus through H1 receptor in pancreatic carcinoma cells. Mol Med Report. 2010; 3: 103-9.
89. Theoharides TC, Kempuraj D, Kourelis T, et al. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci. 2008; 1144: 74-82.
90. Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology. 2010; 59: 180-9.
91. Pedotti R, DeVoss JJ, Youssef S, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA. 2003; 100: 1867-72.
92. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol. 2010; 161: 755-67.
93. Ruffell B, Coussens LM. Histamine restricts cancer: nothing to sneeze at. Nat Med. 2011; 17: 43-4.
94. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9: 162-74.
95. Yang XD, Ai W, Asfaha S, et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med. 2011; 17: 87-95.
96. Thoren FB, Aurelius J, Martner A. Antitumor properties of histamine in vivo. Nat Med. 2011; 17: 537; author reply -8.
97. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006; 108: 88-96.
98. Donskov F, Hokland M, Marcussen N, et al. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma-results from a randomised phase II trial. Br J Cancer. 2006; 94: 218-26.
99. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep. 2009; 11: 433-41.
100. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010; 3: 497-516.
101. Molderings GJ, Brettner S, Homann J, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011; 4: 10.
102. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004; 55: 419-32.
103. Hadzijusufovic E, Peter B, Gleixner KV, et al. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 2010; 38: 896-907.
104. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108: 2366-72.
105. Laine E, Chauvot de Beauchene I, Perahia D, et al. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol. 2011; 7: e1002068.
106. Dobigny C, Saffar JL. H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol. 1997; 173: 10-8.
107. Fitzpatrick LA, Buzas E, Gagne TJ, et al. Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci USA. 2003; 100: 6027-32.
108. Delsignore JL, Dvoretsky PM, Hicks DG, et al. Mastocytosis presenting as a skeletal disorder. Iowa Orthop J. 1996; 16: 126-34.
109. Lesclous P, Guez D, Saffar JL. Short-term prevention of osteoclastic resorption and osteopenia in ovariectomized rats treated with the H(2) receptor antagonist cimetidine. Bone. 2002; 30: 131-6.
110. Pochampally RR, Ylostalo J, Penfornis P, et al. Histamine receptor H1 and dermatopontin: new downstream targets of the vitamin D receptor. J Bone Miner Res. 2007; 22: 1338-49.
111. Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol. 1982; 49: 249-51.
112. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002; 32: 489-98.
113. Matsuki M, Sato N, Matsuda K, et al. Brugada syndrome whose ST-segment changes were enhanced by antihistamines and antiallergenic drugs. Intern Med. 2009; 48: 1009-13.
114. Vischer UM, de Moerloose P. von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease. Crit Rev Oncol Hematol. 1999; 30: 93-109.
115. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest. 1987; 79: 600-8.
116. Jilma B, Pernerstorfer T, Dirnberger E, et al. Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. J Lab Clin Med. 1998; 131: 151-6.
117. Zarei S, Frieden M, Rubi B, et al. Dopamine modulates von Willebrand factor secretion in endothelial cells via D2-D4 receptors. J Thromb Haemost. 2006; 4: 1588-95.
118. Wang KY, Tanimoto A, Yamada S, et al. Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am J Pathol. 2010; 177: 713-23.
119. Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Pediatr Clin North Am. 2011; 58: 1281-300, xii.
120. LaBella FS, Brandes LJ. Interaction of histamine and other bioamines with cytochromes P450: implications for cell growth modulation and chemopotentiation by drugs. Semin Cancer Biol. 2000; 10: 47-53.
121. Yang R, Hey JA, Aslanian R, et al. Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology. 2002; 66: 128-35.
122. Imamura I, Watanabe T, Hase Y, et al. Histamine metabolism in patients with histidinemia: determination of urinary levels of histamine, N tau-methylhistamine, imidazole acetic acid, and its conjugate(s). J Biochem. 1984; 96: 1925-9.
123. Correa-Fiz F, Reyes-Palomares A, Fajardo I, et al. Regulatory cross-talk of mouse liver polyamine and methionine metabolic pathways: a systemic approach to its physiopathological consequences. Amino Acids. 2012; 42: 577-95.
124. Smits RA, Adami M, Istyastono EP, et al. Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H4 receptor inverse agonists. J Med Chem. 2010; 53: 2390-400.
125. Hussein G, Sankawa U, Goto H, et al. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006; 69: 443-9.
126. Mozsik G, Past T, Abdel Salam OM, et al. Interdisciplinary review for correlation between the plant origin capsaicinoids, non-steroidal antiinflammatory drugs, gastrointestinal mucosal damage and prevention in animals and human beings Inflammopharmacology. 2009; 17: 113-50.
127. Melgarejo E, Medina MA, Sanchez-Jimenez F, et al. Targeting of histamine producing cells by EGCG: a green dart against inflammation? J Physiol Biochem. 2010; 66: 265-70.
128. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr. 2003; 133: 3275S-84S.
129. Zhang G, Miura Y, Yagasaki K. Suppression of adhesion and invasion of hepatoma cells in culture by tea compounds through antioxidative activity. Cancer Lett. 2000; 159: 169-73.
130. Tosetti F, Ferrari N, De Flora S, et al. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002; 16: 2-14.
131. Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 2005; 11: 2735-46.
132. Hung PF, Wu BT, Chen HC, et al. Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways. Am J Physiol Cell Physiol. 2005; 288: C1094-108.
133. Liang YC, Chen YC, Lin YL, et al. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3, 3′-digallate. Carcinogenesis. 1999; 20: 733-6.
134. Song XZ, Bi ZG, Xu AE. Green tea polyphenol epigallocatechin-3-gallate inhibits the expression of nitric oxide synthase and generation of nitric oxide induced by ultraviolet B in HaCaT cells. Chin Med J (Engl). 2006; 119: 282-7.
135. Noh SU, Cho EA, Kim HO, et al. Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in NC/Nga mice by suppressing macrophage migration inhibitory factor. Int Immunopharmacol. 2008; 8: 1172-82.
136. Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003; 97: 1442-6.
137. Ahn WS, Yoo J, Huh SW, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003; 12: 383-90.
138. Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011; 102: 317-23.
139. Gundimeda U, McNeill TH, Schiffman JE, et al. Green tea polyphenols potentiate the action of nerve growth factor to induce neuritogenesis: possible role of reactive oxygen species. J Neurosci Res. 2010; 88: 3644-55.
140. Ranjith-Kumar CT, Lai Y, Sarisky RT, et al. Green tea catechin, epigallocatechin gallate, suppresses signaling by the dsRNA innate immune receptor RIG-I. PLoS One. 2010; 5: e12878.
141. Katiyar SK, Matsui MS, Elmets CA, et al. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol. 1999; 69: 148-53.
142. Hsu S, Yamamoto T, Borke J, et al. Green tea polyphenol-induced epidermal keratinocyte differentiation is associated with coordinated expression of p57/KIP2 and caspase 14. J Pharmacol Exp Ther. 2005; 312: 884-90.
143. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res. 2010; 302: 71-83.